Загрузка...
A233 VEDOLIZUMAB FOR STEROID & INFLIXIMAB-REFRACTORY ICI-COLITIS
BACKGROUND: Immune checkpoint inhibitors (ICI), such as anti-PD1, improve survival in melanoma, renal carcinoma and prostate cancer. However, by disinhibiting the immune system, these treatments cause significant immune-related adverse events (irAE), including colitis. For ICI-colitis, guidelines su...
Сохранить в:
| Опубликовано в: : | J Can Assoc Gastroenterol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7043547/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz047.232 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|